Two new drugs in clinical trials are extending survival for women with metastatic HER2-positive breast cancer that had progressed with previous treatment. One of the drugs was effective for brain metastasis, which is particularly difficult to treat. Results from both studies were reported in the New England Journal of Medicine.
Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.
Janice is 32 years old and was recently diagnosed with triple-negative breast cancer. She is receiving neoadjuvant chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel. Janice is a nationally recognized performer (vocal and piano) and is distraught over the possibility of losing her hair or developing chemotherapy-induced peripheral neuropathy and mouth sores. She asks the nurse what can be done to prevent those unwanted side effects.
The concept of providing comfort is at the core of my identity as a nurse, and I have always been drawn to the palliative care component of what we do as oncology nurses. Because it wasn’t part of my roles, I was less confident in my knowledge and understanding of chemotherapy administration, but I often thought, “Palliative care, yeah, I’ve got this!”
And then I learned how little I knew.
On April 8, 2020, the U.S. Food and Drug Administration (FDA) approved encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.
One of the first people we learn about in nursing school is Florence Nightingale. During the Crimean War, she noticed soldiers were dying because of disease, not from the effects of war. Because of Nightingale’s observations and interventions, handwashing and infection control became standard practices in nursing.
Thrombotic events are the second-leading cause of death in patients with cancer after the disease itself. An estimated 4%–20% of patients experience venous thromboembolism at some stage on the cancer journey.
The business shutdowns and mandatory social distancing from the COVID-19 coronavirus pandemic brought the country’s economy to the brink. Last week, the Title VIII Nursing Workforce Reauthorization Act of 2019 was included as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act’s comprehensive, landmark legislation. The $2 trillion aid package was geared to promote public health and boost economic confidence.
Deployed to provide expert medical advice about the COVID-19 coronavirus pandemic, U.S. Surgeon General Jerome Adams, MD, made media rounds the first week of April 2020. Although the news he shared wasn’t positive, it was a necessary message that the United States needed to hear.
If current trends continue, the world will see a 60% increase in cancer diagnoses through 2040, the World Health Organization said in its February 2020 Report on Cancer: Setting Priorities, Investing Wisely, and Providing Care for All.